NASDAQ:CYTR - Nasdaq -
0.31
-0.07 (-18.38%)
The current stock price of CYTR is 0.31 null. In the past month the price decreased by -39.29%. In the past year, price decreased by -76.87%.
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
Cytrx Corp.
11726 SAN VICENTE BOULEVARD SUITE 650
LOS ANGELES CA 90049
CEO: Steven A. Kriegsman
Phone: 310-826-5648
The current stock price of CYTR is 0.31 null. The price decreased by -18.38% in the last trading session.
The exchange symbol of Cytrx Corp. is CYTR and it is listed on the Nasdaq exchange.
CYTR stock is listed on the Nasdaq exchange.
Cytrx Corp. (CYTR) has a market capitalization of 10.43M null. This makes CYTR a Nano Cap stock.
Cytrx Corp. (CYTR) has a resistance level at 0.54. Check the full technical report for a detailed analysis of CYTR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CYTR does not pay a dividend.
Cytrx Corp. (CYTR) will report earnings on 2022-05-11.
Cytrx Corp. (CYTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).
ChartMill assigns a fundamental rating of 3 / 10 to CYTR. While CYTR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CYTR reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 80.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -4025.6% | ||
ROA | -46.79% | ||
ROE | -52.56% | ||
Debt/Equity | 0 |